The CAR T Cell Revolution
Cancer immunotherapy has been revolutionized by the discovery and development of chimeric antigen receptors (CAR) T cells. CAR T cells are defined as genetically engineered allogeneic T cells that are isolated from blood, developed in the laboratory using viral vectors, and then infused into a patient to fight cancer cells. CAR T cell therapy is type of immunotherapy that has already received two FDA
approvals for tisagenlecleucel (Kymriah) from Novartis
and Axicabtagene ciloleucel (Yescarta) from Kite Pharma/Gilead
. Researchers will soon break ground on how to use CARs for solid tumors.
Accurate Cell Counting Matters
A common thread that unifies researchers and regulators is the importance of immune cell quality in the CAR-T workflow. Ensuring accurate and consistent cell counts, viability, and functionality (e.g. CAR-T cytotoxicity) is why most premier research organizations choose Nexcelom cell counters and image cytometers.